Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues

Liver International

Volumn 31, Issue SUPPL. 1, 2011, Pages 85-89

  Leung, Nancy ^a,b  

^a ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Nucleoside analogues; Nucleotide analogues; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CREATININE; DNA POLYMERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMORBIDITY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPOPHOSPHATEMIA; IMMUNOLOGICAL TOLERANCE; KIDNEY TUBULE ACIDOSIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER NECROSIS; LONG TERM CARE; NEPHROTOXICITY; NONHUMAN; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 78650846855     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02387.x     Document Type: Article

References (20)

1. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-44.
2. Fung J, Lai CL, But D, et al. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol 2008; 103: 1421-6.
3. Sung JJ, Amarapurkar D, Chan HL, et al. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed? Antivir Ther 2010; 15: 607-16.
4. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
5. Lai CL, Chien RW, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
6. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis b enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
7. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
8. Marcellin P, Chang TT, for the adefovir dipivoxil 437 study group, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
9. Hadziyannis SJ, Tassopoulos NC, Adefovir Dipivoxil 438 Study Group et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.. Gastroenterology 2006; 131: 1743-51.
10. Tsang TT, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
11. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
12. Liaw YF, Gane E, GLOBE Study Group et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
13. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51: 787-91.
14. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
15. Liaw YF, Sung JJ, Cirrhosis Asian Lamivudine Multicentre Study Group et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
16. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir verses adefovir in chronic hepatitis B patients with evidence of liver decompensation. Hepatol Int 2010; 4: 168.
17. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
18. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28: 2437-44.
19. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are most effective antiviral agents for CHB - a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
20. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 2010; 15: 145-55.